Literature DB >> 14750048

Effect of risperidone on prolactinoma--a case report.

D N Mendhekar, R C Jiloha, P K Srivastava.   

Abstract

Risperidone induced galactorrhea and hyperprolactinemia have been reported but its role in the growth of prolactinoma is not yet conclusive, due to extreme rarity of such cases. We describe a woman, suffering from Bipolar Disorder-manic episode, who exhibited prolactinoma while on risperidone therapy. The withdrawal of risperidone resulted in disappearance of prolactinoma though her prolactin level remained elevated along with persistent galactorrhea. The change to olanzapine therapy did not show much change in serum prolactin level and galactorrhea. Ultimately, only adding of bromocriptine resulted in disappearance of symptoms of prolactinemia and normal serum prolactin level was achieved and galactorrhea stopped. Further study is recommended to find out relationship between the growth of prolactinoma and risperidone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750048     DOI: 10.1055/s-2004-815474

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  3 in total

1.  Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".

Authors:  Danielle Coppola; Shanker Thiagarajah; Hong Qiu; David Hough
Journal:  Innov Clin Neurosci       Date:  2013-02

2.  A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report.

Authors:  Gail T Arcari; Asante K Mendes; Robert B Sothern
Journal:  Innov Clin Neurosci       Date:  2012-09

Review 3.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.